Integrative genetic and transcriptomic analysis identifies candidate genes and compounds for Fragile X syndrome and autism spectrum disorder
- 1Florida Atlantic University
Abstract
Fragile X syndrome (FXS) is the most commonly known monogenic cause of autism spectrum disorder (ASD), yet how FXS biology relates to polygenic architecture of idiopathic ASD remains poorly defined. We integrated publicly available genetic data relevant to ASD and FXS, including population case-control risk, symptom discordance within monozygotic twin pairs, contrasts between ASD and other psychiatric disorders, and genetic variation associated with circulating plasma fragile X messenger ribonucleoprotein (FMRP) abundance. These data were used to identify associated genes and pathways across tissues and prioritize small molecules predicted to reverse genetically associated transcriptional signatures. Cross-tissue analysis identified XRN2 as the strongest association for population ASD risk and PPP3CA as the strongest association with FMRP abundance, providing distinct candidate links to ASD and FXS biology. We found no evidence that population ASD risk and symptom discordance within monozygotic twin pairs share common-variant architecture after accounting for linkage disequilibrium, suggesting that these phenotypes capture at least partially distinct sources of genetic signal. Connectivity mapping identified candidate compounds across eight genetic signatures, including several with biologically plausible mechanisms. Together, these findings provide a genetics-anchored framework for connecting FXS and ASD biology and for prioritizing candidate therapeutic mechanisms and compounds, while highlighting methodological safeguards needed for reliable integrative genomic drug repurposing.
Related
- Integrative single-cell and bulk transcriptomic analysis identifies monocyte/macrophage senescence-associated candidate genes in pulmonary arterial hypertension
- Integrative transcriptomic analysis and preclinical validation identify lansoprazole as a therapeutic candidate for preeclampsia
- Spatial transcriptomic analysis identifies tnni2a.3 as a candidate associated with intermuscular bone formation in zebrafish
- Integrated transcriptomic analysis identifies Paternally Expressed Gene 10 as a novel candidate biomarker associated with aggressive features in liposarcoma
- Integrative genotype-environment association and single-cell transcriptomic analyses identify candidate mechanisms of environmental adaptation in pigs.
BibTeX
@misc{zhang2026integrative,
title = {{Integrative genetic and transcriptomic analysis identifies candidate genes and compounds for Fragile X syndrome and autism spectrum disorder}},
author = {W. Zhang and J. Yan and M. DeGiorgio},
howpublished = {bioRxiv},
year = {2026},
month = oct,
doi = {10.64898/2026.10.03.756403},
url = {https://www.biorxiv.org/content/10.64898/2026.10.03.756403v1},
note = {CC BY},
}
RIS
TY - UNPB
TI - Integrative genetic and transcriptomic analysis identifies candidate genes and compounds for Fragile X syndrome and autism spectrum disorder
AU - W. Zhang
AU - J. Yan
AU - M. DeGiorgio
PY - 2026
DA - 2026/10/03
PB - bioRxiv
DO - 10.64898/2026.10.03.756403
UR - https://www.biorxiv.org/content/10.64898/2026.10.03.756403v1
AB - Fragile X syndrome (FXS) is the most commonly known monogenic cause of autism spectrum disorder (ASD), yet how FXS biology relates to polygenic architecture of idiopathic ASD remains poorly defined. We integrated publicly available genetic data relevant to ASD and FXS, including population case-control risk, symptom discordance within monozygotic twin pairs, contrasts between ASD and other psychiatric disorders, and genetic variation associated with circulating plasma fragile X messenger ribonucleoprotein (FMRP) abundance. These data were used to identify associated genes and pathways across tissues and prioritize small molecules predicted to reverse genetically associated transcriptional signatures. Cross-tissue analysis identified XRN2 as the strongest association for population ASD risk and PPP3CA as the strongest association with FMRP abundance, providing distinct candidate links to ASD and FXS biology. We found no evidence that population ASD risk and symptom discordance within monozygotic twin pairs share common-variant architecture after accounting for linkage disequilibrium, suggesting that these phenotypes capture at least partially distinct sources of genetic signal. Connectivity mapping identified candidate compounds across eight genetic signatures, including several with biologically plausible mechanisms. Together, these findings provide a genetics-anchored framework for connecting FXS and ASD biology and for prioritizing candidate therapeutic mechanisms and compounds, while highlighting methodological safeguards needed for reliable integrative genomic drug repurposing.
ER -